Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci

被引:5
|
作者
Mao, Yifan V. [1 ,2 ]
Hughes, Elena G. [3 ]
Steinmetz, David [4 ]
Troob, Samantha [5 ]
Kim, Jiyoon [6 ]
Tseng, Chi-Hong [6 ]
Fishbein, Gregory A. [7 ]
Sajed, Dipti P. [7 ]
Livhits, Masha J. [3 ]
Yeh, Michael W. [3 ]
Lee, Denise [8 ]
Angell, Trevor E. [9 ]
Wu, James X. [3 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Sect Endocrine Surg, 10833 Le Conte Ave,72-228 CHS, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Sect Endocrine Surg, Los Angeles, CA USA
[4] Icahn Sch Med Mt Sinai Hosp, Div Metab Endocrine & Minimally Invas Surg, New York, NY USA
[5] Icahn Sch Med Mt Sinai Hosp, New York, NY USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA
[8] Icahn Sch Med Mt Sinai Hosp, Div Surg Oncol & Endocrine Surg, New York, NY USA
[9] Keck Sch Med USC, Div Endocrinol & Diabet, Los Angeles, CA USA
关键词
MANAGEMENT; CARCINOMA; DIAGNOSIS; CARRIERS;
D O I
10.1001/jamaoto.2023.4376
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
IMPORTANCE Standard treatment for patients with medullary thyroid cancer (MTC) consists of total thyroidectomy with central neck dissection, but the rationale for bilateral surgery in patients with unilateral disease on ultrasonography remains unclear. OBJECTIVE To determine the presence of occult contralateral disease (lesions not seen on preoperative ultrasonography) in patients with MTC as a rationale for total thyroidectomy. DESIGN, SETTING, AND PARTICIPANTS This multi-institutional, retrospective cohort study was conducted from September 1998 to April 2022 in academic medical centers and included patients with MTC who underwent thyroidectomy with preoperative imaging. MAIN OUTCOMES AND MEASURES The primary end point was the prevalence of sonographically occult foci of MTC in the contralateral lobe among patients with sporadic MTC. RESULTS The cohort comprised 176 patients with a median age at diagnosis of 55 years (range, 2-87 years), 69 (57.6%) of whom were female. Genetic testing was performed in 109 patients (61.9%), 48 (27.5%) of whom carried germline RET variants. Initial surgical management consisted of total thyroidectomy (161 [91.0%]), lobectomy followed by completion thyroidectomy (7 [4.0%]), and lobectomy alone (8 [4.5%]). Central and lateral neck dissections were performed as part of initial therapy for 146 patients (83.1%). In the entire cohort of 176 patients, 46 (26.0%) had contralateral foci disease and 9 (5.1%) had occult contralateral foci that were not identified on preoperative ultrasonography. Among 109 patients who underwent genetic testing, 38 (34.9%) had contralateral disease, 8 (7.3%) of whom had occult contralateral disease not seen on preoperative ultrasonography. Patients with sporadic MTC experienced a 95.7% reduction in the odds of having a focus of MTC in the contralateral lobe compared with patients with a germline RET variant (odds ratio, 0.043; 95% CI, 0.013-0.123). When adjusting for age, sex, tumor size, and lymph node involvement, the odds ratio of having contralateral MTC in patients with sporadic disease was 0.034 (95% CI, 0.007-0.116). Among patients who underwent lobectomy alone with postoperative calcitonin levels, 5 of 12 (41.7%) achieved undetectable calcitonin levels (<2.0 pg/mL; to convert to pmol/L, multiply by 0.292). CONCLUSIONS AND RELEVANCE The results of this cohort study suggest that a staged approach involving initial thyroid lobectomy could be considered in patients with sporadic MTC and no contralateral ultrasonography findings, with no further surgery if calcitonin levels became undetectable. Further work using prospective randomized clinical trials to evaluate lobectomy as a biochemical cure in patients presenting with unilateral disease is warranted.
引用
收藏
页码:209 / 214
页数:6
相关论文
共 50 条
  • [1] Extent of surgery for unilateral papillary thyroid cancer with nonsuspicious contralateral nodules by ultrasound
    Xu, Siyuan
    Huang, Hui
    Xian, Keyao
    Wang, Xiaolei
    Xu, Zhengang
    Liu, Shaoyan
    Liu, Jie
    ENDOCRINE, 2024, 86 (01) : 276 - 283
  • [2] The Prevalence of Occult Medullary Thyroid Carcinoma at Autopsy
    Valle, Laticia A.
    Kloos, Richard T.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (01) : E109 - E113
  • [3] Extent of resection in intrathyroidal medullary thyroid cancer
    Lorenz, K.
    Machens, A.
    Siebolts, U.
    Dralle, H.
    CHIRURG, 2020, 91 (12): : 1017 - 1024
  • [4] The Effect of Extent of Surgery and Number of Lymph Node Metastases on Overall Survival in Patients with Medullary Thyroid Cancer
    Esfandiari, Nazanene H.
    Hughes, David T.
    Yin, Huiying
    Banerjee, Mousumi
    Haymart, Megan R.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (02) : 448 - 454
  • [5] Should the Prevalence of Incidental Thyroid Cancer Determine the Extent of Surgery in Multinodular Goiter?
    Kaliszewski, Krzysztof
    Strutynska-Karpinska, Marta
    Zubkiewicz-Kucharska, Agnieszka
    Wojtczak, Beata
    Domoslawski, Pawel
    Balcerzak, Waldemar
    Lukienczuk, Tadeusz
    Forkasiewicz, Zdzislaw
    PLOS ONE, 2016, 11 (12):
  • [6] Extent of Surgery for Low-Risk Differentiated Thyroid Cancer
    McDow, Alexandria D.
    Pitt, Susan C.
    SURGICAL CLINICS OF NORTH AMERICA, 2019, 99 (04) : 599 - +
  • [7] Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer
    Machens, Andreas
    Hoffmann, Florian
    Sekulla, Carsten
    Dralle, Henning
    ENDOCRINE-RELATED CANCER, 2009, 16 (04) : 1291 - 1298
  • [8] Increasing Thyroid Cancer Rate and the Extent of Thyroid Surgery in Korea
    Sung, Myung-Whun
    Park, Bumjung
    An, Soo-Youn
    Hah, J. Hun
    Jung, Young Ho
    Choi, Hyo Geun
    PLOS ONE, 2014, 9 (12):
  • [9] Latest Progress in Risk-Adapted Surgery for Medullary Thyroid Cancer
    Machens, Andreas
    Lorenz, Kerstin
    Brandenburg, Tim
    Fuehrer, Dagmar
    Weber, Frank
    Dralle, Henning
    CANCERS, 2024, 16 (05)
  • [10] How I treat medullary thyroid cancer
    Kiesewetter, B.
    Riss, P.
    Scheuba, C.
    Raderer, M.
    ESMO OPEN, 2021, 6 (03)